Insulin Degludec
Brand name: Tresiba Flextouch U-100
Rank #33 of 500 drugs by total cost
$567.8M
Total Cost
597,178
Total Claims
$567.8M
Total Cost
20,772
Prescribers
$951
Cost per Claim
84,301
Beneficiaries
1,129,297
30-Day Fills
$27K
Avg Cost/Provider
29
Avg Claims/Provider
About Insulin Degludec
Insulin Degludec (sold as Tresiba Flextouch U-100) was prescribed 597,178 times by 20,772 Medicare Part D providers in 2023, costing the program $567.8M. At $951 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
| 35 | Fluticasone Propion/Salmeterol (Advair Diskus) | $523.2M | 1,289,942 |
| 36 | Varicella-Zoster Ge/As01b/Pf (Shingrix) | $514.4M | 2,419,884 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology